Comparing the current results to its competitors, Inventiva S A reported Revenue decrease in the 4 quarter 2025 year on year by -48.13 %, despite the revenue increase by the most of its competitors of 52.4 %, recorded in the same quarter.
Inventiva S A 's Comment on Competition and Industry Peers
The company operates in a competitive global market for the commercialization of new drugs, facing competition from major pharmaceutical firms, specialty pharmaceutical companies, biotechnology companies, and generic drug manufacturers. Competitors may develop or market therapies that are more effective, safer, less costly, or achieve regulatory or reimbursement approval more rapidly. Notable competitors include Madrigal, which received FDA approval for Rezdiffra to treat MASH with moderate to advanced liver fibrosis and conditional marketing authorization from the European Commission. Novo Nordisk announced positive Phase 3 clinical trial results for semaglutide and obtained FDA approval for Wegovy for MASH treatment. Other companies conducting Phase 3 clinical trials for MASH include Boehringer Ingelheim, Eli Lilly, Akero Therapeutics (a subsidiary of Novo Nordisk), GSK, Roche, and 89bio. Additional companies evaluating investigational MASH medications include Sagimet, Boston Pharmaceuticals, Altimmune, AstraZeneca, NorthSea, Terns, Viking, BMS, and Pfizer.
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.
Liquidia Corporation is a biopharmaceutical company that develops and commercializes products using its proprietary PRINT® technology to design and produce precision-engineered medicines. The company focuses on creating therapies for respiratory diseases and other areas of high unmet medical need, leveraging the potential of its unique particle engineering platform.
Galapagos Nv's business model is centered around the development and commercialization of innovative medicines. They leverage their expertise in drug discovery and development to collaborate with partners in the healthcare industry, focusing on the advancement of novel therapies to address unmet medical needs.
Sources:
Inventiva S a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inventiva S a versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
